Ozempic Cuts Breast Cancer Risk by 30%: What the Landmark ASCO Study Found

A study presented at the 2026 ASCO Annual Meeting is getting attention for a genuinely striking finding: women taking GLP-1 drugs like Ozempic and Wegovy were roughly 30% less likely to develop breast cancer. It’s a real result worth understanding properly — which means being precise about both what it shows and what it doesn’t, rather than treating a 30% headline number as the whole story.

What the study actually found

Researchers at Penn Medicine analyzed electronic health records from 111,646 women aged 45 to 80, all with a BMI of 25 or higher, who underwent breast imaging between January 2022 and June 2025. Women using GLP-1 medications had 35.1% lower odds of developing breast cancer across the full study group, and 30.5% lower odds in a more carefully matched comparison subgroup — the more statistically robust of the two figures. The findings were published in JCO Oncology Practice, a respected oncology journal, and a dedicated clinical trial is now being planned to test the finding directly.

How strong is this evidence, honestly?

This is the part that matters most and gets glossed over the most. The study is observational — researchers tracked outcomes in women already taking GLP-1 drugs, rather than randomly assigning some women to take them and others not to. That distinction isn’t a technicality. It means we cannot yet say the drugs caused the reduction in cancer risk, only that the two are strongly associated. Women who get prescribed and stay on GLP-1 medications may differ from women who don’t in ways that also affect cancer risk — better healthcare engagement, different baseline health status, and other factors that a database analysis, however large, can’t fully control for.

What makes the signal hard to dismiss despite that limitation: the sample size (over 111,000 women), the consistency between the full-cohort and matched-subgroup results, and the fact that the direction of effect lines up with a genuinely plausible biological mechanism rather than an unexplained statistical anomaly. That combination is why a follow-up clinical trial — which can actually test causation — is now being planned. Until that trial reports, this is a strong hypothesis, not a settled fact.

Why this is biologically plausible

Three mechanisms are under consideration, and none of them requires stretching the science:

Less body fat means less estrogen. Body fat produces estrogen, which fuels roughly 70% of breast cancers. Significant GLP-1-driven weight loss may be removing one of the more powerful drivers of hormone-sensitive tumors.

Reduced systemic inflammation. Obesity is a state of chronic low-grade inflammation, and GLP-1 receptors exist on immune cells as well as in the gut and brain — reducing that inflammation may create a less favorable environment for cancer to develop.

A possible direct receptor effect. Some researchers suspect semaglutide may have an anti-tumor action independent of weight loss entirely, based on early animal data. This is the least-established of the three and the one I’d weight least heavily right now.

What I’d actually tell a patient about this

If you’re already on a GLP-1 drug for diabetes or weight management, this is genuinely reassuring background — you may be getting a cancer-risk benefit on top of the metabolic ones you already know about, and it’s worth mentioning at your next visit. If you’re not on one, this is not yet a reason to start taking a prescription medication purely for cancer prevention — the evidence is still at the “strong hypothesis” stage, not the “start taking this to prevent cancer” stage. Where it is worth a specific conversation with your doctor is if you’re already in a higher-risk group for breast cancer for other reasons and are also a reasonable candidate for GLP-1 therapy on metabolic grounds — in that overlap, this finding is one more data point worth weighing.

The bottom line

A 111,000-woman study found a 30-35% association between GLP-1 use and lower breast cancer odds — a real, biologically plausible, and hard-to-dismiss signal, presented at one of oncology’s most respected conferences. It is not yet proof of cause and effect, and a clinical trial is underway specifically to find out. Treat it as a genuinely promising open question rather than a settled reason to start or avoid these medications.